Olanzapine treatment for patients with schizophrenia and substance abuse

Journal of Substance Abuse Treatment

Volumn 21, Issue 4, 2001, Pages 217-221

  Littrell, Kimberly H ^a,b   Petty, Richard G ^a,b   Hilligoss, Nicole M ^a   Peabody, Carol D ^a   Johnson, Craig G ^a  

^a Promedica Research Center   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Comorbidity; Dual diagnosis; Olanzapine; Schizophrenia; Substance abuse

Indexed keywords

ALCOHOL; AMPHETAMINE DERIVATIVE; CANNABIS; COCAINE; OLANZAPINE; PSYCHEDELIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MENTAL DISEASE; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; REMISSION; SCHIZOIDISM; SCHIZOPHRENIA; SUBSTANCE ABUSE;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; MALE; PIRENZEPINE; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 0035669490     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0740-5472(01)00205-7     Document Type: Article

References (40)

1. Safety and efficacy of risperidone in substance abusers with psychosis
2. Decreased substance use in chronically psychotic patients treated with clozapine (Letter to the editor)
3. Self reports of the interaction between substance abuse and schizophrenia
4. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients
5. A rating scale for drug-induced akathisia
6. Substance abuse in schizophrenia: service utilization and cost
7. Exclusion criteria of DSM-III
8. Depression in alcoholic schizophrenic patients
9. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia
10. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy
11. Antipsychotic standard of care: redefining the definition of atypical antipsychotics
12. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse
13. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?
14. Acute effects of drug abuse on schizophrenic patients; clinical observations and patients' self reports
15. Relationship between concurrent substance abuse in psychiatric patients and neuroleptic dosage
16. Substance abuse among the chronically mentally ill
17. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia
18. Clozpaine for comorbid substance abuse disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?
19. Predicting the 'revolving door' phenomenon among patients with schizophrenic, schizoaffective, and affective disorders
20. Abbreviated instrument to measure hope: development and psychometric evaluation
21. The positive and negative syndrome scale (PANSS) for schizophrenia
22. Diagnosis and management of substance use disorders among inpatients with schizophrenia
23. Substance use disorder and the early course of illness in schizophrenia and affective psychosis
24. Prevalence and patterns of dual diagnosis among psychiatric inpatients
25. Reduction of comorbid substance abuse with clozapine (Letter to the editor)
26. Olanzapine attentuates the reinforcing effects of cocaine
27. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health setting
28. Six-month outcomes for patients who switched to olanzapine treatment
29. Medication noncompliance and substance abuse among patients with schizophrenia
30. Suppression of alcohol preference in rats induced by risperidone, a serotonin 5-HT2 and dopamine D2 antagonist
31. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study
32. Pharmacological treatment of substance-abusing schizophrenic patients
33. A rating scale for extrapyramidal side effects
34. Clozapine for substance-abusing schizophrenic patients (letter)
35. Treatment of schizophrenia in subjects with substance use disorders: a review
36. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse
37. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey